Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Show more

Location: 1560 Trapelo Road, Waltham, MA, 02451, United States | Website: https://www.dyne-tx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.704B

52 Wk Range

$6.36 - $25.00

Previous Close

$16.42

Open

$16.52

Volume

665,280

Day Range

$16.40 - $17.24

Enterprise Value

2.032B

Cash

791.9M

Avg Qtr Burn

-93.93M

Insider Ownership

0.44%

Institutional Own.

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DYNE-251 Details Duchenne muscular dystrophy	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DYNE-101 Details Myotonic Dystrophy Type 1	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.